Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex–induced lung disease
Nelli Shushakova, … , Reinhold E. Schmidt, J. Engelbert Gessner
Nelli Shushakova, … , Reinhold E. Schmidt, J. Engelbert Gessner
Published December 15, 2002
Citation Information: J Clin Invest. 2002;110(12):1823-1830. https://doi.org/10.1172/JCI16577.
View: Text | PDF
Article Autoimmunity

C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex–induced lung disease

  • Text
  • PDF
Abstract

Research Article

Authors

Nelli Shushakova, Julia Skokowa, Jurriaan Schulman, Ulrich Baumann, Jörg Zwirner, Reinhold E. Schmidt, J. Engelbert Gessner

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Functional detection of bioactive C5a in BALF from IC-challenged mice. P...
Functional detection of bioactive C5a in BALF from IC-challenged mice. Pulmonary IC inflammation was induced in C57BL/6 mice and assayed for IC-induced C5a (IC). Controls received anti-OVA Ab without OVA antigen (Ab). (a) Chemotactic activity was determined at the indicated times by Transwell migration assays of neutrophils (PMNs isolated from bone marrow of C57BL/6 and C5aR–/– mice or C57BL/6 PMNs preincubated with or without anti-C5aR mAb 20/70) elicited with 300 μl of BALF pools obtained from five mice of the IC and Ab treatment groups. (b) Assays using an optimal concentration of 50 ng/ml rhC5a instead of BALF served as positive controls for the indicated PMN preparations. Results are expressed as the percentage of PMNs loaded into the upper chamber that had migrated to the bottom well (means ± SEM for five individual experiments). Differences in PMN migration of C57BL/6 and C5aR–/– mice, or after anti-C5aR 20/70 mAb treatment, were significant (*P < 0.05, **P < 0.001).
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts